Reports link Dupixent to T-cell lymphomas; see eligibility and evidence Why Lawsuits Are Being Filed Patients across the U.S. are filing lawsuits alleging that Dupixent® (dupilumab)—prescribed for eczema, asthma, nasal polyps, and other conditions—may trigger, worsen, or mask a cancer of the immune system called cutaneous T-cell lymphoma (CTCL). Core claims focus on whether the…